IL-AIT-WORLDWIDE
3.10.2022 17:03:40 CEST | Business Wire | Press release
Global supply chain solutions leader AIT Worldwide Logistics has entered into a new Civil Reserve Air Fleet (CRAF) partnership with Ypsilanti, Michigan-based Kalitta Air. The strategic alliance continues AIT’s longstanding designation as a CRAF-sponsored freight forwarder, enabling the company to continue critical supply chain support for United States Transportation Command (USTRANSCOM) missions, while also increasing access to global routes, capacity, and charters for customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005635/en/
AIT Worldwide Logistics forms CRAF partnership with Kalitta Air (Photo: Business Wire)
“For more than 10 years, we’ve been proud and always at the ready to support USTRANSCOM through the CRAF program,” said AIT’s Chief Business Officer, Greg Weigel. “As AIT continues to grow our global footprint and scope, securing a CRAF partnership with an airline that has similar global reach, with some of the world’s largest cargo aircraft made perfect sense to our team—and that’s Kalitta.”
Kalitta operates B747-400 and B777F freighters for long-range international charters and scheduled services. Their fleet also includes B737F’s as well as smaller jet and turboprop aircraft serving the North American market with support for time-critical charter, life sciences and aircraft on ground missions.
“We’re excited to enter into a new phase of collaboration with AIT,” said Vice President Cargo Marketing for Kalitta Air, Lynn Stauffer. “They’ve been a trusted partner for a long time, and we look forward to working together to support USTRANSCOM for years to come.”
Weigel added that Kalitta has been an AIT core carrier for decades, especially vital for the company’s government and aerospace business. The airline is also one of AIT’s top three carriers since the COVID-19 pandemic.
Cleared to land and take off from military bases all over the world and with aircraft strategically positioned at hubs across United States, Europe, Asia, and South America, Kalitta has the capacity to move cargo anywhere in the world in a matter of hours. And, according to Weigel, the airline has already worked with AIT on hundreds of international charter projects.
Established in 1951, CRAF is a readiness program used to provide a significant portion of the nation’s air mobility resources when the Department of Defense (DOD) airlift exceeds the capability of military aircraft.
This cooperative, voluntary program also involves the U.S. Department of Transportation and the U.S. civil air carrier industry in a partnership to augment DOD aircraft capability during a national defense related crisis.
Air carriers volunteer their aircraft to the CRAF program through contractual agreements with the air mobility command and, in return, participating companies are given preference in carrying commercial peacetime cargo and passenger traffic for DOD.
In addition to the company’s CRAF partnership, AIT is also a member of the Transport Asset Protection Association, is a certified Customs Trade Partnership Against Terrorism compliant provider and is a sustaining member of the National Defense Transportation Association.
For more information about AIT’s participation in the CRAF program, https://www.aitworldwide.com/craf-sponsored-forwarder.
For more information about Kalitta Air, visit kalittaair.com.
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, food, government, healthcare, high-tech, industrial and life sciences. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes door-to-door deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 100 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005635/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom